Arsenal Acquires Specialty CRO Synchrogenix, Merges With Certara

Arsenal Capital Partners announced that it has acquired Synchrogenix Information Strategies, a leading regulatory writing and related services firm. Concurrent with the acquisition will be Synchrogenix’s merging with Certara, a leading global technology-enabled drug development and drug safety consultancy acquired by Arsenal last December 2013.

Partner at Arsenal and Co-Head of the firm's Healthcare Group, Stephen McLean, said, “Pharmaceutical companies are looking for greater value and increased synergies from their outsourcing partners. Adding the complementary services Synchrogenix offers to the Certara portfolio will allow Certara to provide its preclinical and clinical pharmacology customers with end-to-end drug development consulting and writing services, including preparation of regulatory submissions such as the Biologic License Application, Investigational New Drug and New Drug Applications.”

Certara offers scientific informatics and analytics including molecular modeling, population-based simulations, clinical trial simulations, and pharmacokinetic analyses. The company has over 225 employees located at offices in the U.S., U.K., and Japan.

Synchrogenix is currently the largest independent regulatory-writing contract research organization worldwide, with more than 50 permanent regulatory writers and editors on staff located across North America, Asia, and Europe. The company offers a full range of regulatory writing including pre-clinical, clinical, CMC, and drug safety writing as well as global regulatory submission services.

Synchrogenix CEO Ellen Barrosse said, “Having worked with our talented staff to build Synchrogenix from the ground up, I was looking for a like-minded company that shared our strong work ethic and focus on excellent customer service and high-quality results. We have found a great match in Arsenal and Certara, and I look forward to expanding the range of services that we offer to all of our customers.” CEO Barrosse will remain head of Synchrogenix following the company’s acquisition.

Arsenal stated that it was attracted to Synchrogenix’s quality of work and global network of regulatory experts. The firm believes Synchrogenix’s global writing and submission services will add to Certara’s drug development consulting expertise.